Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

NCT01193842 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

107

Enrollment

NIH

Sponsor class

Conditions

AIDS-Related Plasmablastic Lymphoma
AIDS-Related Primary Effusion Lymphoma
Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Ann Arbor Stage I Grade 3 Follicular Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma
HIV Infection
Plasmablastic Lymphoma
Primary Effusion Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
DRUG: Etoposide
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Prednisone
BIOLOGICAL: Rituximab
DRUG: Vincristine Sulfate
DRUG: Vorinostat

Sponsor

National Cancer Institute (NCI)